CCND1 and neoplasm: Although we cannot exclude the possibility that part of the negative impact of cyclin D1 overexpression might be explained by endocrine treatment resistance, the significant association between high cyclin D1 expression and aggressive biological features of the tumor at diagnosis indicates that adjuvant treatment resistance cannot be the only explanation.